多参数MRI联合[18F]PSMA-1007 PET/CT对前列腺癌病理升级的预测价值:一项多中心研究
本研究回顾性分析163例活检确诊的局限性前列腺癌患者,构建整合术前mpMRI与[18F]PSMA-1007 PET/CT参数的预测模型,用于预测从系统穿刺活检(SB)到根治性前列腺切除术(RP)标本的病理升级。55例(33.7%)发生病理升级,联合模型AUC为0.803(95%CI:0.734~0.861),外部验证确认模型可靠性。
要点
- 55例(33.7%)发生病理升级,联合模型AUC为0.803(95%CI:0.734~0.861)。
- ADCmean-ADCmin(P=0.035)、SUVmax(P=0.003)、SB最高ISUP分级及PET/CT多灶性(P=0.007)为独立预测因素。
- 联合模型可有效预测前列腺癌病理升级,有助于更精确的治疗风险分层。
核心结论
- 整合mpMRI与[18F]PSMA-1007 PET/CT参数的预测模型可有效预测前列腺癌病理升级,有助于更精确的治疗风险分层。
研究设计与样本
- 回顾性分析2019年1月至2022年6月经活检确诊的163例局限性前列腺癌患者,术前接受mpMRI和[18F]PSMA-1007 PET/CT检查。
- 比较有无病理升级患者的临床和影像特征,通过单因素和多因素分析评估预测因素并构建模型,用ROC曲线确定最佳截断值并评估模型性能。
- 选择两个外部中心的患者作为验证队列。
主要发现
- 55例(33.7%)发生病理升级。
- 多因素分析显示ADCmean-ADCmin(P=0.035)、SUVmax(P=0.003)、SB最高肿瘤分级ISUP分级组1 vs 2(P=0.001)、1 vs 3(P<0.001)、1 vs 4(P<0.001)及[18F]PSMA-1007 PET/CT上的多灶性(P=0.007)为病理升级的独立预测因素。
- 联合模型AUC为0.803(95%CI:0.734~0.861),显示稳健的判别能力。
- 外部验证确认了模型的可靠性和预测能力。
关键数值与推荐
- 联合模型AUC为0.803(95%CI:0.734~0.861)。
- ADCmean-ADCmin(P=0.035)、SUVmax(P=0.003)、ISUP分级组1 vs 2(P=0.001)、1 vs 3(P<0.001)、1 vs 4(P<0.001)及PET/CT多灶性(P=0.007)为独立预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to develop a predictive model that integrates parameters derived from preoperative multiparametric magnetic resonance imaging (mpMRI) and [18F]PSMA-1007 PET/CT for reliably predicting pathological upgrading from systematic biopsy (SB) to radical prostatectomy (RP) specimens. METHODS: We ultimately retrospectively analyzed 163 patients with biopsy-confirmed localized prostate cancer (PCa) who underwent preoperative mpMRI and [18F]PSMA-1007 PET/CT scans between January 2019 and June 2022. Clinical and imaging characteristics were compared between patients with and without pathological upgrading. Predictive factors for pathological upgrading were evaluated through univariate and multivariable analyses. Predictive models were constructed based on the identified parameters. Receiver operating characteristic (ROC) curves were utilized to determine optimal cutoff values and to evaluate model performance. Additionally, patients from two external centers were selected as a validation cohort. RESULTS: A total of 55 (33.7%) cases experienced pathological upgrading. Multivariate analysis revealed that ADCmean - ADCmin (P = 0.035); SUVmax (P = 0.003); highest tumor grade at SB, ISUP grade group (ISUP GG) 1 vs. 2 (P = 0.001), ISUP GG 1 vs. 3 (P < 0.001), ISUP GG 1 vs. 4 (P < 0.001); and multifocality on [18F]PSMA-1007 PET/CT (P = 0.007) were independent predictors for pathological upgrading. The combined model achieved an area under the curve (AUC) of 0.803 (95% CI: 0.734 to 0.861), indicating robust discriminative power. External validation confirmed the model's reliability and predictive ability. CONCLUSION: Our predictive model, integrating mpMRI and [18F]PSMA-1007 PET/CT parameters, effectively forecasts pathological upgrading in PCa, allowing for more precise treatment risk stratification.
引用
- Xu J, Chen H, Chen L, et al. The predictive value of multiparametric MRI combined with [18F]PSMA-1007 PET/CT for the pathological upgrade in prostate cancer: a multicenter study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40338303. doi:10.1007/s00259-025-07311-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。